Philips India has now stirred a price war in the healthcare life-saving diagnostic equipment space offering its pocket-sized ECG and ultrasound at 50 per cent lower than those available in the market. This led the company to commence discussions with the state governments and convince them to opt for affordable healthcare diagnostics to help save lives of patients in the event of a cardiac and maternal emergency and save lives.
The basic model of ECG-100 is priced at Rs. 25,000 and ultrasound VISIQ is Rs. 10.5 lakh . The big advantage is that two equipments are pocket sized convenient for any general practitioner to carry during a health emergency. It could also be handled with ease by a paramedic at primary healthcare centres in remote areas.
The two products designed and developed at the Phillips Innovation Centre (PIC) in Bengaluru which is one among its key R&D locations of the 59 research centres globally.
India currently has 1050 cardiac centres. The country accounts for 60 million people with cardiovascular disease (CVD) and 6 million fatal cases. In the last ten years, CVD went up from 36 million to 60 million. The answer to this problem is preventive and screening to detect CVD. The number of Maternal mortality is also a serious issue. Therefore, every public and private healthcare centre in the country needs the two equipment which are dependable, simple-to-use and affordable, said Ravi Ramaswamy, senior director, head, Healthcare, Philips Innovation Centre.
“We have initiated our talks with the state governments including Punjab and Karnataka which are now assessing and analysing the two equipment, Jitesh Mathur, senior director, PCCI, Reach Strategic Key Accounts, Philips Healthcare, told Pharmabiz
In fact the innovation in the ECG is its sophisticated transducer which can be connected to an Android- based tablet smartphone, added Mathur.
In the case of the ultrasound VISIQ, the equipment is a compact single miniaturised device allowing Ob/Gyn specialists to scan expectant women not just in labour rooms but in remote areas to prevent maternal mortality, said Sujit Kumar, general manager, Ultrasound, Philips Healthcare.
“India and other growth geographies are increasingly important, as centres of innovation excellence for us. This is a fundamental part of our innovation strategy particularly in healthcare where we continue to invest in centres of excellence having a global presence and local relevance. PIC is one of the 59 Philips R&D centres globally, of which 13 are in Asia and 3 in Latin America. In 2013, Philips invested over EUR 1.7 billion in research and development globally,” said Jim Andrew, Chief Strategy & Innovation Officer .
According to Krishna Kumar, vice chairman and managing director, Philips India, both ECG and ultrasound are here to address the complex challenges of India healthcare.
First naloxone treatment specifically designed to be given by family members or caregivers
The U.S. Food and Drug Administration today approved a prescription treatment that can be used by family members or caregivers to treat a person known or suspected to have had an opioid overdose. Evzio (naloxone hydrochloride injection) rapidly delivers a single dose of the drug naloxone via a hand-held auto-injector that can be carried in a pocket or stored in a medicine cabinet.
It is intended for the emergency treatment of known or suspected opioid overdose, characterized by decreased breathing or heart rates, or loss of consciousness.
Drug overdose deaths, driven largely by prescription drug overdose deaths, are now the leading cause of injury death in the United States – surpassing motor vehicle crashes. In 2013, the Centers for Disease Control and Prevention reported the number of drug overdose deaths had steadily increased for more than a decade.
Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for overdose. However, existing naloxone drugs require administration via syringe and are most commonly used by trained medical personnel in emergency departments and ambulances.
“Overdose and death resulting from misuse and abuse of both prescription and illicit opioids has become a major public health concern in the United States,” said Bob Rappaport, M.D., director of the Division of Anesthesia, Analgesia, and Addiction Products in the FDA’s Center for Drug Evaluation and Research. “Evzio is the first combination drug-device product designed to deliver a dose of naloxone for administration outside of a health care setting. Making this product available could save lives by facilitating earlier use of the drug in emergency situations.”
Evzio is injected into the muscle (intramuscular) or under the skin (subcutaneous). Once turned on, the device provides verbal instruction to the user describing how to deliver the medication, similar to automated defibrillators. Family members or caregivers should become familiar with all instructions for use before administering to known or suspected persons to have had an opioid overdose. Family members or caregivers should also become familiar with the steps for using Evzio and practice with the trainer device, which is included along with the delivery device, before it is needed.
Because naloxone may not work as long as opioids, repeat doses may be needed. Evzio is not a substitute for immediate medical care, and the person administering Evzio should seek further, immediate medical attention on the patient’s behalf.
In one pharmacokinetic study of 30 patients, a single Evzio injection provided equivalent naloxone compared to a single dose of naloxone injection using a standard syringe. The use of Evzio in patients who are opioid dependent may result in severe opioid withdrawal. Abrupt reversal of opioid depression may result in nausea, vomiting, sweating, accelerated heart rate (tachycardia), increased blood pressure, uncontrollable trembling (tremulousness), seizures and cardiac arrest.
The FDA reviewed Evzio under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products. The product was granted a fast-track designation, a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Evzio is being approved ahead of the product’s prescription drug user fee goal date of June 20, 2014, the date the agency was originally scheduled to complete review of the drug application.
Evzio’s approval is also the result of efforts by several federal agencies. Naloxone has been a part of the White House’s Office of National Drug Control Policy’s National Drug Control Strategy since 2012. The FDA co-chairs an HHS inter-departmental working group on naloxone, which helped coordinate an April 12, 2012, meeting regarding access to naloxone products.
Evzio is manufactured for kaléo, Inc., of Richmond, Va.
A resolution passed by the general body of the Tamil Nadu branch of the Indian Pharmaceutical Association (IPA) has demanded that government of India should soon take steps to set up a national council for pharmaceutical research, which should be known as Indian Council for Pharmaceutical Research (ICPR).
Presenting the resolution in the meeting, Dr Thirumalai Elango, the Registrar of Tamil Nadu Pharmacy Council said there are several significant national councils for various industrial and medical researches. Indian Council for Agricultural Research (ICAR), Indian Council for Medical Research (ICMR), Indian Council for Ayurvedic Research (ICAR), Indian Council for Siddha Research (ICSR), Indian Council of Unani Research (ICUR), Indian Council for Naturopathy Research (ICNR), Indian Council for Scientific Research (ICSR)..etc are some examples. Unfortunately, the government of India has so far not created a Council for Pharmaceutical Research, he said in his resolution.
Citing examples, Dr Elango said the only industry in the country which is recession proof is the pharmaceutical industry and is growing at a rate of 15 per cent every year. With the dynamic growth of the industry, India is called the ‘pharmacy for the rest of the world’. Our country exports medicines to more than 220 countries. Other than medicine no other product is exported like this. Even then, the government has so far not given due recognition to the pharmaceutical industry, he added.
Later the meeting passed another resolution that like medical, engineering and agricultural subjects, pharmacy subjects like pharmaceutics, pharmaceutical chemistry, pharmacognosy and forensic pharmacy should be included in the Group 1 Examinations conducted by the Union Public Services Commission (UPSC). Inclusion of pharmacy subjects will enable the pharmacy graduates to appear for the national competitive examinations and to get into public administration on par with medical, engineering and agricultural graduates.
A third resolution presented in the meeting demanded the creation of a separate ministry for pharmacy and pharmaceuticals. It said that at present the pharmacy profession is controlled by many ministries like health ministry, ministry of petroleum & chemicals, ministry of commerce, ministry of forests, etc. The pharmacy education is under health ministry and under the higher education ministry (PCI & AICTE). The drugs control administration comes under ministry of health. Pharmaceutical industry comes under ministry of industry & commerce. Pollution control is controlled by ministry of environment & forests. Too many ministries to control a single pharmacy profession is not advisable and helpful for development. So the government should create a Ministry of Pharmacy and Pharmaceuticals, demanded the resolution.
All the three resolutions were passed unanimously by the general body.
The U.S. Food and Drug Administration recently approved Oralair to treat allergic rhinitis (hay fever) with or without conjunctivitis (eye inflammation) that is induced by certain grass pollens in people ages 10 through 65 years. Oralair is the first sublingual (under the tongue) allergen extract approved in the United States. After administration of the first dose at the health care provider’s office, where the patient can be observed for potential adverse reactions, Oralair can be taken at home.